Surgeons at the OHSU Casey Eye Institute led the first in-body CRISPR gene editing procedure in 2020 as part of the Phase 1/2 BRILLIANCE clinical trial. Updated results show most participants with a rare inherited form of blindness experienced measurable improvement after receiving the experimental treatment. (OHSU/Kristyna Wentz-Graff)